Alcon (ALC) Gets a Hold Rating from Morgan Stanley

Morgan Stanley analyst Cecilia Furlong maintained a Hold rating on Alcon (ALCResearch Report) yesterday and set a price target of $92.00. The company’s shares closed last Thursday at $77.45.

According to TipRanks.com, Furlong is a 4-star analyst with an average return of 25.3% and a 50.9% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Edwards Lifesciences, and Irhythm Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $86.55 average price target, implying a 9.4% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a CHF69.00 price target.

See the top stocks recommended by analysts >>

Alcon’s market cap is currently $39.3B and has a P/E ratio of 119.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More